Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

This phase II trial studies how well naive T-cell depletion works in preventing chronic graft-versus-host disease in children and young adults with blood cancers undergoing donor stem cell transplant. Sometimes the transplanted white blood cells from a donor attack the body's normal tissues (called graft versus host disease). Removing a particular type of T cell (naive T cells) from the donor cells before the transplant may stop this from happening.

Trial Details

NCT ID
NCT03779854
Phase
PHASE2
Sponsor
Fred Hutchinson Cancer Center
Status
RECRUITING
Cancer Type
Acute Lymphoblastic (ALL) Leukemia
Interventions
  • Total-Body Irradiation
  • Thiotepa
  • Fludarabine
  • Cyclophosphamide
  • Busulfan
  • Allogeneic Bone Marrow Transplantation
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Washington D.C., District of Columbia, United States|38.89511,-77.03637
  • Atlanta, Georgia, United States|33.749,-84.38798
  • Iowa City, Iowa, United States|41.66113,-91.53017
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • The patient must have one of the following diagnoses and be considered to be an appropriate candidate for allogeneic HCT by the study site principa…
  • Acute lymphoblastic leukemia (ALL) with \< 5% marrow blasts.
  • Acute myeloid leukemia (AML) with \< 25% marrow blasts.
  • Other acute leukemia (OAL) or related neoplasm (including but not limited to acute biphenotypic leukemia \[ABL\], ambiguous lineage \[ALAL\], mixed…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Acute Lymphoblastic (ALL) Leukemia Trials on Trialify →